Please notice!
This website uses cookies to provide necessary site functionality and improve your online experience. By using this website, you agree to the use of cookies as outlined in the
Privacy Statement
.

As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is
committed to providing our customers around the world with the highest quality products.
In addition to direct selling in more than 20 countries in North America, Europe and
Asia/Pacific, Miltenyi Biotec also provides support for our customers through an
extensive distributor network covering dozens of additional countries.

As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is
committed to providing our customers around the world with the highest quality products.
In addition to direct selling in more than 20 countries in North America, Europe and
Asia/Pacific, Miltenyi Biotec also provides support for our customers through an
extensive distributor network covering dozens of additional countries.

Graft engineering

Graft engineering in autologous and allogeneic HSC transplantation

20 years of experience in clinical-grade cell separation for graft manipulation

Worldwide use of cell separation strategies for engineering of stem cell grafts

CD34+ cell enrichment and various options for T cell depletion with the CliniMACS® System

While HSCT is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and non-malignant diseases, it is also associated with severe side effects. The CliniMACS® Cell Separation System offers a variety of tools that enables the removal of T cells, T cells subsets, B cells, and other unwanted cells from hematopoietic stem cell grafts to overcome relapse and side effects like graft-versus-host disease. Different clinical strategies are being evaluated to engineer stem cell grafts for different purposes based on Miltenyi Biotec's cell separation technologies and clinical grade antibodies for different epitopes.